I-34 Thu Thuy Nguyen Modelling the impact of fecal ciprofloxacin concentrations on fecal counts of resistant Enterobacteriaceae in piglets treated with ciprofloxacin: towards new means to control the spread of resistance? Wednesday 10:15-11:45 |
I-37 Elisabet Nielsen Target Attainment Analysis to Evaluate Dosing Regimens of an Oral β-Lactam Antibioic Wednesday 10:15-11:45 |
I-57 Dinko Rekic External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1 infected patients Wednesday 10:15-11:45 |
II-08 Alessandro Schipani Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies Wednesday 15:10-16:40 |
II-13 Satoshi Shoji Population Pharmacokinetics/Pharmacodynamics of Ampicillin/Sulbactam in Patients with Moderate or Severe Community-Acquired Pneumonia Wednesday 15:10-16:40 |
II-34 Nadia Terranova Modelling of protozoa dynamics and drug effects in a murine model of malaria infection Wednesday 15:10-16:40 |
II-52 Max von Kleist PK-PD Modelling of the Reverse Transcriptase Inhibitor Tenofovir and Quantification of its Prophylactic Efficacy against HIV-1 Infection Wednesday 15:10-16:40 |
II-64 Chao Zhang Model-based evaluation of the pharmacokinetic differences between adults and children administered lopinavir and ritonavir in combination with rifampicin Wednesday 15:10-16:40 |
III-02 Mona Alameddine Pragmatic Approach for Interpreting Antiretroviral Drug Concentrations Based on a Systematic Review of Population Pharmacokinetic Studies Thursday 10:05-11:35 |
III-08 Eduardo Asín-Prieto Population pharmacokinetics of piperacillin in critically ill patients undergoing continuous renal replacement therapies Thursday 10:05-11:35 |
III-18 Kirsten Bergmann Comparing a mechanistic with an empirical approach to assess resistance development of antibacterials in vitro. Thursday 10:05-11:35 |
III-19 Julie Bertrand Population Pharmacokinetic-Pharmacogenetic study of Efavirenz in combination with anti-TB treatment in HIV-Infected Cambodian Patients Thursday 10:05-11:35 |
III-29 Margreke Brill Population pharmacokinetic model for cefazolin in serum and subcutaneous adipose tissue in morbidly obese and normal weight patients Thursday 10:05-11:35 |
III-37 Ayyappa Chaturvedula Development of population pharmacokinetic model for Tenofovir using sparsely sampled subject data Thursday 10:05-11:35 |
III-53 Paolo Denti Population pharmacokinetics of ritonavir-boosted darunavir together with efavirenz in healthy volunteers Thursday 10:05-11:35 |
IV-33 Stefanie Hennig Pharmacokinetics of tobramycin do not differ in patients with and without cystic fibrosis Thursday 15:00-16:30 |
IV-35 Richard Höglund A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated P.falciparum malaria Thursday 15:00-16:30 |
IV-48 Lee Jongtae Population pharmacokinetic analysis of colistin in burn patients Thursday 15:00-16:30 |
IV-57 David Khan In silico predictions of in vitro growth competition experiments between wild type and resistant mutants of E. coli MG1655 exposed to ciprofloxacin Thursday 15:00-16:30 |
IV-58 Frank Kloprogge Population pharmacokinetics of lumefantrine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda Thursday 15:00-16:30 |